Scientific Advisory Committee

Grants management and expert review for SU2C is conducted through the American Association for Cancer Research (AACR) via a rigorous, rapid and transparent process led by our “Blue Ribbon” Scientific Advisory Committee. Chaired by Nobel Laureate Phillip A. Sharp, PhD, the Scientific Advisory Committee is comprised of highly accomplished scientists, physicians, and patient advocates, including:

Phillip A. Sharp, Ph. D., Chairperson, Institute Professor, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA

Brian J. Druker, M.D. Vice Chairperson, Professor of Medicine, Oregon Health Sciences University Cancer Institute, Portland, OR

Arnold J. Levine, Ph.D., Vice Chairperson, Professor, Institute for Advanced Study and Cancer Institute of New Jersy, Princeton, NJ

Julian Adams, Ph.D., Chief Scientific Officer, Infinity Pharmaceuticals, Inc., Cambridge, MA

Tak W. Mak, Ph.D., Chief Scientific Officer, Princess Margaret Hospital, Campbell Family Institute for Breast Cancer Research, Toronto, ON, Canada

Elizabeth H. Blackburn, Ph.D., Morris Herzstein, Professor, Department of Biochemistry and Biophysics University of California, San Francisco, San Francisco, CA

William G. Nelson, V, M.D., Ph.D., Professor, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, Baltimore, MD

Raymond N. Dubois, M.D., Ph.D., Provost and Executive Vice President, UT M. D. Anderson Cancer Center, Houston, TX

Cecil B. Pickett, Ph.D., President, Research and Development, Biogen Idec, Cambridge, MA

Richard B. Gaynor, M.D., Vice President, Cancer Research and Clinical Investigation Eli Lilly and Company, Indianapolis, IN

Vicki L. Sato, Ph.D., Professor of Management Practice, Harvard Business School, Boston, MA

Waun Ki Hong, M.D., Head, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX

Laura K. Shawver, Ph.D., Chief Executive Officer, Phenomix Corp., San Diego, CA

William G. Kaelin, Jr., M.D., Professor, Dana-Farber Cancer Institute, Boston, MA

Ellen V. Sigal, Ph.D. *, Chairperson and Founder, Friends of Cancer Research, Arlington, VA

Richard D. Kolodner, Ph.D., Professor of Medicine, University of California, San Diego Ludwig Institute for Cancer Research, La Jolla, CA

Joseph V. Simone, M.D., President, Simone Consulting, Atlanta, GA

Ronald Levy, M.D., Chief, Division of Oncology, Stanford University, Stanford, CA

Samuel A. Wells, Jr., M.D., Professor of Surgery, Washington University School of Medicine, St. Louis, MO

James E. Williams, Jr. *, Chair-Elect, Intercultural Cancer Council, Camp Hill, PA

* Denotes Patient Advocate committee members selected by the SU2C Advocate Advisory Council